An Early Phase 1 interventional study of Raspberry ketone in Obesity, Diabetes and NAFLD (Nonalcoholic Fatty Liver Disease), sponsored by Nanchang University. Completed at 1 site in China. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-08.
Sponsored by Nanchang University · Early Phase 1, Interventional, and Prevention
To investigate the molecular mechanism of raspberry ketone on regulating obesity, the investigators studied the effect of raspberry ketone intake on FGF21 in plasma.
The age of the volunteers were 18-60 years old, both male and female, without diabetes, hypertension and other diseases.
After ingestion of raspberry ketone (500mg), 2ml of blood was collected at 0 hours, 3 hours and 6 hours , and the FGF21 content in plasma was measured using a commercial reagent kit.
In addition, the investigators also studied the effect of raspberry ketone intake on energy metabolism 0 hours, 0.5 hours, 3 hours and 6 hours after consuming raspberry ketone (500mg).
6,570 studies on the registry are indexed under Obesity; 1,718 are open to participants now.
This study's enrollment of 60 is below the median of 77 across 5,084 interventional studies indexed under Obesity.
Browse Obesity studies →Nanchang University is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
No drugs were taken before the human study
Exclusion Criteria:
Patients with hypertension
Dietary Supplement: Raspberry ketone
Dietary Supplement: Raspberry ketone
Human consumed 500mg of raspberry ketone
Impact of raspberry ketone consumption on plasma FGF21 level
Time frame: Through study completion, an average of 1 year
Impact of raspberry ketone consumption on energy expenditure
The oxygen consumption, heart rate, carbon dioxide production were measured
Time frame: Through study completion, an average of 1 year
Ran from Jan 2024 to primary completion in May 2024, 4 months.
Of 71 non-industry phase 1 interventional studies under Obesity, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 78. This study's 4 months is below that.
Counting every sponsor, half of 328 studies reached it within 11 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanchang University